Biotech Values

[Jonathan Robinson]

JNJ's labs have been very unproductive if you ask me. They seem to have to do major acquisitions to keep the drug division going. Think CNTO (best deal), that company that gave them the failed congestive heart failure drug, AZA, many others.

And I have a feeling that if CNTO had been left alone, they would have been massively profitable by now and some of their deeper pipe would actually be further along independent than as part of JNJ - kind of counter-argumentative as most would have said JNJ had deeper pockets!

Jon